ANDASUBCUTANEOUSINJECTABLE
Approved
Mar 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
15
Mechanism of Action
B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be…
Clinical Trials (5)
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
Started Apr 2025
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Started Jul 2024
115 enrolled
Hereditary Angioedema (HAE)
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
Started Nov 2022
85 enrolled
Hereditary Angioedema (HAE)
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Started Aug 2022
32 enrolled
Hereditary Angioedema (HAE)
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
Started Jan 2021
2 enrolled
Hereditary Angioedema